Downregulation of pro-inflammatory markers IL-6 and TNF-α in rheumatoid arthritis using nano-lipidic carriers of a quinone-based phenolic: an in vitro and in vivo study

Pal, Ravi Raj; Rajpal, Vasundhara; Singh, Neelu; Singh, Sukhveer; Mishra, Nidhi; Singh, Priya; Maurya, Priyanka; Alka,; Saraf, Shubhini A.

doi:10.1007/s13346-022-01221-7

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the percentage of rat paw edema and swelling was significantly decreased in the BER-CTS-BLS treatment group, and the prepared BER-CTS-BLS had a significant anti-inflammatory effect. Other TDDSs of the abovementioned classes of drugs in the treatment of RA are given in Table 3 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 .…”

Section: Tddss In Ra Drug Therapymentioning

confidence: 99%

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Zhao

Cao

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Tddss In Ra Drug Therapymentioning

confidence: 99%

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Zhao

Cao

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…However, the key TFs involved in RA pathogenesis are also associated with biological processes involving homeostasis, and therefore inhibiting these TFs may lead to undesirable side effects. This challenge is currently being addressed by tissue-specific/joint-specific drug delivery via nanocarriers, which increase the specificity and efficacy, while minimizing potential adverse effects ( 17 , 30 , 31 , 35 , 121 , 181 – 183 ).…”

Section: Network Of Tfsmentioning

confidence: 99%

Targeting transcription factors for therapeutic benefit in rheumatoid arthritis

et al. 2023

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a destructive inflammatory autoimmune disease that causes pain and disability. Many of the currently available drugs for treating RA patients are aimed at halting the progression of the disease and alleviating inflammation. Further, some of these treatment options have drawbacks, including disease recurrence and adverse effects due to long-term use. These inefficiencies have created a need for a different approach to treating RA. Recently, the focus has shifted to direct targeting of transcription factors (TFs), as they play a vital role in the pathogenesis of RA, activating key cytokines, chemokines, adhesion molecules, and enzymes. In light of this, synthetic drugs and natural compounds are being explored to target key TFs or their signaling pathways in RA. This review discusses the role of four key TFs in inflammation, namely NF-κB, STATs, AP-1 and IRFs, and their potential for being targeted to treat RA.

show abstract

Multifunctional polymeric nanofibrous scaffolds enriched with azilsartan medoxomil for enhanced wound healing

Alka,

Mishra,

Singh

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Downregulation of pro-inflammatory markers IL-6 and TNF-α in rheumatoid arthritis using nano-lipidic carriers of a quinone-based phenolic: an in vitro and in vivo study

Cited by 4 publications

References 36 publications

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Targeting transcription factors for therapeutic benefit in rheumatoid arthritis

Multifunctional polymeric nanofibrous scaffolds enriched with azilsartan medoxomil for enhanced wound healing

Contact Info

Product

Resources

About